Visual/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year
Authors:
Open Access
- 15 September 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Abstract
To investigate the visual/anatomical outcome of diabetic macular edema (DME) patients lost to follow-up (LTFU) for more than 1 year during intravitreal anti-VEGF treatment. A retrospective review of 182 treatment-naïve DME patients was performed. Among them, we identified patients LTFU for more than 1 year during anti-VEGF treatment. Visual acuity and anatomic outcomes at the first visit, last visit before being LTFU, return visit, and after re-treatment were analyzed and compared with those of DME patients with regular follow-up. Patients who had continuous follow-up visits were assigned to the control group. Sixty patients (33%) with DME were LTFU for more than 1 year during anti-VEGF treatment. Multivariate analysis revealed that the ratio of male (p = 0.004), diabetes mellitus (DM) duration less than 5 years (p = 0.015), and poor early anatomic response (p = 0.012) were higher compared to the control group. Eighteen patients returned to the clinic and received re-treatment. After re-treatment with anti-VEGF, central subfield thickness (CST) was significantly improved to the CST of before LTFU. However, visual acuity did not recover to the level before LTFU (0.63 ± 0.26 vs. 0.45 ± 0.28, p = 0.003). About thirty percent of DME patients were LTFU for more than 1 year. Permanent visual loss was observed in these LTFU patients. Patients with a high risk of LTFU such as male, early DM, and poor response after initial injections should be treated more aggressively to improve the visual outcomes.Keywords
This publication has 35 references indexed in Scilit:
- A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular EdemaOphthalmology, 2014
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular EdemaOphthalmology, 2014
- Defining the Role of Medication Adherence in Poor Glycemic Control among a General Adult Population with DiabetesPLOS ONE, 2014
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III TrialsOphthalmology, 2013
- Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular EdemaOphthalmology, 2013
- The association between adherence to oral anti‐diabetic drugs and hypoglycaemia in persons with Type 2 diabetesDiabetic Medicine, 2013
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Diabetic Macular Edema: Fundus Autofluorescence and Functional CorrelationsInvestigative Ophthalmology & Visual Science, 2011
- Diabetic retinopathyThe Lancet, 2010
- Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort studyBMC Health Services Research, 2009